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Abstract
Background: The chronic care model was proven effective in improving clinical outcomes of diabetes in
developed countries. However, evidence in developing countries is scarce. The objective of this study was to
evaluate the effectiveness of EMPOWER-PAR intervention (based on the chronic care model) in improving clinical
outcomes for type 2 diabetes mellitus using readily available resources in the Malaysian public primary care setting.
Methods: This was a pragmatic, cluster-randomised, parallel, matched pair, controlled trial using participatory action
research approach, conducted in 10 public primary care clinics in Malaysia. Five clinics were randomly selected to
provide the EMPOWER-PAR intervention for 1 year and another five clinics continued with usual care. Patients who
fulfilled the criteria were recruited over a 2-week period by each clinic. The obligatory intervention components
were designed based on four elements of the chronic care model i.e. healthcare organisation, delivery system
design, self-management support and decision support. The primary outcome was the change in the proportion of
patients achieving HbA1c < 6.5%. Secondary outcomes were the change in proportion of patients achieving targets
for blood pressure, lipid profile, body mass index and waist circumference. Intention to treat analysis was performed
for all outcome measures. A generalised estimating equation method was used to account for baseline differences
and clustering effect.
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Results: A total of 888 type 2 diabetes mellitus patients were recruited at baseline (intervention: 471 vs. control:
417). At 1-year, 96.6 and 97.8% of patients in the intervention and control groups completed the study, respectively.
The baseline demographic and clinical characteristics of both groups were comparable. The change in the
proportion of patients achieving HbA1c target was significantly higher in the intervention compared to the control
group (intervention: 3.0% vs. control: −4.1%, P < 0.002). Patients who received the EMPOWER-PAR intervention were
twice more likely to achieve HbA1c target compared to those in the control group (adjusted OR 2.16, 95% CI 1.34–
3.50, P < 0.002). However, there was no significant improvement found in the secondary outcomes.
Conclusions: This study demonstrates that the EMPOWER-PAR intervention was effective in improving the primary
outcome for type 2 diabetes in the Malaysian public primary care setting.
Trial registration: Registered with: ClinicalTrials.gov.: NCT01545401. Date of registration: 1st March 2012.
Keywords: Type 2 diabetes mellitus, Chronic disease management, Chronic care model, Multifaceted intervention,
Clinical outcomes, Primary care, Family medicine
Background
It is estimated that 415 million people suffer from type 2
diabetes mellitus (T2DM) with the global prevalence of
8.8% [1]. T2DM is the 7th leading cause of death world-
wide [2]. The number is predicted to increase beyond
642 million people within the next 25 years [1] and
deaths attributable to T2DM will double by 2030 [2].
Malaysia, a multi-ethnic nation consisting predomin-
antly of Malays, Chinese and Indians, is also experien-
cing a T2DM epidemic. Prevalence of T2DM among
adults aged ≥ 18 years old has dramatically increased
from 6.3% in 1986, 8.3% in 1996, and 11.6% in 2006 to
an astounding 15.2% in 2011 [3]. It has been projected
that Malaysia would have a total of 3.2 million people
with T2DM by the year 2030 [1]. T2DM was the 9th
leading cause of disease burden in Malaysia as measured
by the Disability-Adjusted Life Years (DALYs) [4] and
the 6th leading cause of premature death as measured
by the number of years of life lost (YLLs) [5].
Majority of T2DM patients in Malaysia are being man-
aged in the public primary care setting as the services
are heavily subsidised by the government and patients
pay minimal sum for treatment [6]. In the private sector,
payments are largely borne by the patients or private
medical insurance [7]. Without medical insurance, it is
often too expensive for patients with T2DM to receive
care in this setting. Therefore, the over-subsidised and
resource-constrained public primary care sector is
overloaded to provide care to the majority of T2DM
patients [6, 7].
Even though Malaysian public primary care providers
struggle hard to meet evidence-based standards of care
as recommended by the clinical guidelines, many fall
short due to the high workload and constraints in terms
of staffing and other resources [7]. Widespread imple-
mentation of multidisciplinary team management and
delivery of self-management support for T2DM are
hampered by shortages of trained personnel [7]. Drug
availability is still limited, especially the newer and more
expensive hypoglycaemic agents [7]. The increasing bur-
den of managing T2DM presents enormous challenges
to the public primary care workforce, resulting in sub-
optimal management, poor clinical outcomes and high
complication rates [7, 8]. Analysis of the National
Diabetes Registry (NDR) involving 70,889 adults with
T2DM in the Malaysian public primary care setting
demonstrated poor glycaemic control with mean HbA1c
of 8.3, and 52.6% received sub-optimal management of
related cardiovascular (CV) risk factors [8].
Evidence from developed countries has shown that
clinical outcomes of T2DM can be improved with multi-
faceted interventions based on the chronic care model
(CCM) [9–12]. This model promotes that better chronic
disease outcome is achieved when a well-coordinated,
proactive healthcare team interacts productively with
empowered and motivated patients [13–15]. The CCM
consists of 6 interrelated key elements which include
healthcare organisation, delivery system design, clinical
information system, patient self-management support,
decision support and use of community resources [13–
15]. However, evidence on the effectiveness of the CCM
in developing countries is still insufficient. To date, there
were only a handful of published studies using CCM in
this setting. A small before-and-after study of structured
diabetes clinics in primary care in the United Arab Emir-
ates showed that the intervention was successful in im-
proving adherence to diabetes guidelines and increased
some aspects of satisfaction with diabetes care [16].
However, the intervention did not result in a statistically
significant improvement in clinical outcomes [16]. A re-
cent before-and-after study of multifaceted interventions
based on the CCM in the Northern Philippines showed
significant decrease in HbA1c (median, from 7.7 to 6.9%,
P < 0.000) and significant improvement in the proportion
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achieving good glycaemic control among the participants
(37.2 to 50.6%, P = 0.014) [17]. The CORFIS study is the
only published evidence on the effectiveness of CCM in
Malaysia [18]. It was conducted in the private primary
care setting and showed significant improvement in the
proportion of hypertension patients achieving target
blood pressure (BP) after 6 months of intervention [18].
Therefore, further research is needed to evaluate the
effectiveness of CCM-based intervention among T2DM
patients in the Malaysian public primary care setting,
where a larger proportion of these patients are receiving
care and where limited resources are often stretched
thin. Given the constraints in the public primary care
setting, successful implementation of the CCM requires
pragmatic utilisation of existing health care resources
and participatory approach aiming at empowering pri-
mary care providers to improve clinical practice [19, 20].
This led to the objective of this study which was to
evaluate the effectiveness of the EMPOWER-PAR inter-
vention (multifaceted chronic disease management
strategies designed based on the CCM) in improving
clinical outcomes for patients with T2DM using existing




This was a pragmatic, cluster-randomised, parallel,
matched pair, controlled trial using participatory action
research (PAR) approach [20] in public primary care
clinics from two states in Malaysia, which were Wilayah
Persekutuan Kuala Lumpur (WPKL) and Selangor (SEL).
The pragmatic study design was chosen to maximise ex-
ternal validity to ensure that the results can be general-
ised to the public primary care system in Malaysia [21].
The study protocol was registered with the clinicaltrial.-
gov (NCT01545401) and was published in 2014 [22].
This paper reports the findings from the T2DM arm of
the study and the reporting is done in accordance with
the extension of CONSORT Statements on reporting
pragmatic trials and cluster randomised trials [23, 24].
Site selection and recruitment
All 34 public primary care clinics led by Family Medi-
cine Specialists (FMS) in SEL and WPKL were invited to
participate in this study. The FMS were invited to attend
a briefing session on the study objectives and method-
ology. Detailed explanations were given regarding the
pragmatic nature of the study design, the eligibility cri-
teria and the concept of PAR approach in implementing
the EMPOWER-PAR intervention.
The site feasibility questionnaire (SFQ) was then dis-
tributed to all FMS who attended the briefing session.
This questionnaire was also sent via email to all FMS
who did not attend the session. The SFQ was divided
into four sections which included site investigator’s in-
formation; clinic location and type, workload and staff-
ing; information on the pre-existing delivery of care for
T2DM; and site investigator’s interest in participating in
this study. In the ‘pre-existing delivery of care for
T2DM’ section of the SFQ, the ‘green book’ referred to
the booklets which are widely used in majority of the
public primary care clinics in Malaysia. It is made out of
two books, an A5-size medical record booklet which is
kept by the clinic and a smaller A6-size ‘mini green
book’ which is kept by the patient. The ‘green book’ con-
tains information on symptoms, evidence of complica-
tions, medications, vital signs and investigations
including blood results. The ‘mini green book’ records
similar clinical data for follow-up treatment purposes.
However, it does not contain CV risk or self-
management information.
The SFQ was returned to the investigators after two
weeks, either by post or email. The clinics were then
assessed for the following eligibility criteria:
1. had ≥ 500 patients with T2DM in the registry.
2. had an FMS who were keen to participate and
willing to lead the team.
3. had the capacity and willing to implement the
obligatory components of the EMPOWER-PAR
intervention.
4. was located within 70 km from the central
laboratory as the blood samples were transported
back to the centre for analysis.
Out of the 34 sites, only 20 fulfilled the eligibility cri-
teria to enter the study. Finding of the site feasibility
assessment is provided in the Additional file 1. These 20
clinics were then matched according to their geograph-
ical locations (urban or sub-urban), workload and staff-
ing into 10 pairs. Clinics were matched according to
these covariates as they were likely to affect the outcome
variables, as the intervention was delivered at the cluster
(clinics) level. This was employed to ensure similarity
between the intervention and control group.
The investigators used computer generated tables to
randomly select five out of the 10 matched-pairs to be
included into the study. Then, one clinic in each pair
was randomly allocated into the intervention or control
arms.
Patient recruitment
Consecutive T2DM patients who attended the clinics
within the 2-week recruitment period were given the pa-
tient information sheet and interviewed by the investiga-
tors in the waiting area. Screening was conducted to
identify eligible participants based on the inclusion and
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exclusion criteria. Eligible patients were then invited to
participate and informed consents were obtained from
those who were willing to participate.
Inclusion criteria
Males and females aged ≥ 18 years who:
1. were diagnosed with T2DM, or on treatment for
T2DM
2. and received follow-up care for T2DM in the same
clinic at least once in the last 1 year
Exclusion criteria
1. type 1 diabetes mellitus
2. receiving renal dialysis
3. presented with severe hypertension (HPT) (Systolic
BP > 180 mmHg and/or Diastolic BP > 110 mmHg)
at recruitment
4. diagnosed with conditions resulting in secondary
hypertension
5. diagnosed with circulatory disorders requiring
referral to secondary care over the last one year (e.g.
unstable angina, heart attack, stroke, transient
ischaemic attacks)
6. receiving shared care at primary and secondary care
centres for complications of T2DM
7. pregnant
8. enrolled in another study
During the 1-year intervention period, all patients in
the intervention arm were required to be seen at least
twice by the Chronic Disease Management (CDM) team
from each clinic. Patients who did not comply with the
follow-up requirement were considered as lost to follow-
up. During the course of the study, there was no limit to
the number of clinic visits that a patient was allowed to
make in either the intervention or control groups.
The EMPOWER-PAR intervention
The EMPOWER-PAR intervention was designed based
on the six interrelated elements of the CCM. The details
of its development have been described in the study
protocol [22]. It consisted of three obligatory compo-
nents and two optional components utilising readily
available and existing resources in the Malaysian public
primary care setting. The aim was to have a productive
interaction between the empowered CDM team and the
informed, empowered T2DM patients [22]. Table 1 sum-
marised the components of the EMPOWER-PAR inter-
vention according to their respective CCM elements.
The EMPOWER-PAR intervention was unique as it
was designed based on the entire CCM elements using
readily available resources. Although there was robust
evidence supporting the individual elements of the
CCM, there is still paucity in the literature regarding im-
plementation of the entire CCM as a multifaceted inter-
vention, especially in a resource-constrained primary
care setting. With the exception of several studies [16–
18], previous studies implementing the CCM elements
as multifaceted interventions have been conducted in
developed countries [9–12]. Similar to CORFIS [18], the
EMPOWER-PAR was not designed to differentiate the
effectiveness of individual CCM elements in its multifa-
ceted intervention.
Implementation process of the intervention
The EMPOWER-PAR intervention was delivered for a
period of 1-year. The intervention clinics received the
EMPOWER-PAR intervention package, which consisted
of CDM Workshops, intervention tools, facilitation and
support. The process evaluation of this complex
intervention was conducted in accordance with the
United Kingdom Medical Research Council guidance
[25]. Figure 1 summarised the delivery structure of the
EMPOWER-PAR intervention.
The implementation process was conducted in 3
phases as below:
Phase 1: Formation and training of the CDM Team
Each intervention clinic identified five CDM Team
members who were then trained in the CDM Work-
shops. Details of the CDM Workshops development, ob-
jectives and content were already published in the
protocol paper [22]. During the workshop, the CDM
Table 1 The obligatory and the optional components of the
EMPOWER-PAR intervention and the related CCM elements
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Team was trained on team building and to define their
roles and responsibilities. They were also trained on how
to empower their T2DM patients with knowledge and
skills to self-manage their condition using the Global
CV Risks Self-Management Booklet as a tool. This in-
cluded improving the skills of the CDM Team to pro-
vide accurate information to their patients regarding the
nature of the disease, possible complications, treatment
goals and the importance of taking their medications ap-
propriately. Emphasis was given on how to improve
provider-patient communication, which has been shown
to enhance patient self-management behaviours over
time [26].
The PAR approach [20] was applied in implementing
the EMPOWER-PAR interventions to ensure that the
CDM Team were empowered to make the choice of ac-
tions within their constraints to improve their patients’
health outcomes. Each clinic had unique challenges
which include shortages or high turnover of medical
staff and allied health personnel, high patient load, lim-
ited clinic space and time constraints. These clinics also
had existing chronic disease care system. Therefore it
was impractical and inappropriate to apply a rigid inter-
vention program [22]. With this in mind, the CDM
Team from each clinic prepared a proposed intervention
plan at the end of the workshop series, which considered
their unique constraints. The proposed plan described
the roles and responsibilities of each team member, the
methods to implement the three obligatory intervention
components, and also the steps needed to achieve their
goals and ways to overcome their barriers. The planning
to implement the optional components was also made
by the clinics which had adequate resources. The
process of PAR gave the autonomy to the health care
providers to determine how best to improve the quality
of their patient care [20].
Phase 2: Distribution and utilisation of the intervention
tools
The CDM Team was expected to utilise the Malaysian
CPG and the Quick References (QR) on the Manage-
ment of T2DM [27] to support their clinical decision
making during consultations, and the Global CV Risks
Self-Management Booklet to support patients’ empower-
ment and self-management. This booklet was designed
as an educational resource material for patients to
understand their conditions, risk factors, potential com-
plications, control targets and how to self-manage their
conditions. Details on the development and content of
this booklet were already published in the protocol
paper [22]. Patients were expected to bring this booklet
during their follow-up appointments and the CDM
Team members were expected to utilise this booklet to
review their progress and empower them with self-
management skills. This booklet differs from the trad-
itional ‘mini green book’ which serves as communication
tool between doctors. The ‘mini green book’ was not de-
signed as an educational resource material for patients
Fig. 1 Delivery Structure of the EMPOWER-PAR Intervention
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and therefore, contains clinical data which may not be
readily understood by them.
Phase 3: Facilitation and support to implement the
intervention
The intervention clinics received facilitation and support
throughout the study period to implement the interven-
tion. An intervention review workshop was also con-
ducted 6 months after the commencement of
intervention to allow interactions among the participat-
ing clinics and solve any arising problems. CPG training
and feedback with regards to their baseline clinical out-
comes were also delivered during this workshop [22].
Monitoring the implementation fidelity of the
intervention
Monitoring the implementation fidelity is an essential
part of the process evaluation of a complex intervention
[25, 28]. In this study, the facilitators monitored the im-
plementation fidelity of the intervention in each clinic to
ensure that it was delivered as intended throughout the
1-year period. Data on implementation fidelity was col-
lected by the facilitators through observation during the
site visits. Fidelity monitoring was focused on the imple-
mentation of obligatory components of the EMPOWER-
PAR intervention. Observation data was captured in
writing by the facilitators using a standardised report
form, which was later compiled by the chief facilitator.
Feedback was also gathered from the CDM Team with
regards to their barriers and challenges in implementing
the intervention. Facilitators also gave feedback to the
intervention clinics with regards to their performance.
Meetings amongst the facilitators were conducted at
least three times over the 1-year study period to discuss
the implementation fidelity in each clinic. Variations in
the implementation fidelity between each clinic were
minimised through these strategies of facilitation, sup-
port and close monitoring.
The control
The control clinics continued with usual care with no
additional intervention during the 1-year period. Allied
health personnel were available in the control clinics but
they may not be functioning as a team in managing
T2DM. The control clinics have access to CPG as these
are readily available resources. However, they did not re-
ceive CPG training and CPG utilisation was not empha-
sised or monitored. The CDM workshop modules and
intervention tools were made available to the control
clinics at the end of the study. There was no other add-
itional resource allocated to either the intervention or
the control group.
Outcome measures
Outcome measures were obtained from both interven-
tion and control clinics at baseline and one year after
the commencement of the intervention. The target
values for the primary and secondary outcome measures
were based on the national CPG for T2DM [27]. Defin-
ition of the outcome categories at 1-year follow-up is
summarised in the Additional file 2.
Primary outcome
Primary outcome was measured by the change in the
proportion of patients achieving glycaemic target of
HbA1c < 6.5% (48 mmol/mol).
Secondary outcome
Secondary outcomes were measured by changes in the
proportions of patients achieving the following targets:
 BP ≤ 130/80 mmHg
 BMI < 23 kg/m2
 Waist Circumference (WC) < 90 cm for men, <
80 cm for women
 Total cholesterol (TC) ≤ 4.5 mmol/L
 Triglycerides (TG) ≤ 1.7 mmol/L
 Low density lipoprotein cholesterol (LDL-c) ≤
2.6 mmol/L
 High density lipoprotein cholesterol (HDL-c) ≥
1.1 mmol/L
Data collection and study procedures
Data were obtained from both the intervention and con-
trol clinics at baseline and at 1-year follow-up. Baseline
data were collected in June 2012 – December 2012, the
intervention was delivered in January 2013 – December
2013 and outcome data were collected in January 2014 –
June 2014.
All interviewers and investigators were trained regard-
ing the study procedures prior to the conduct of the
study to minimise variability in the method of data col-
lection. At baseline, an interview and physical examina-
tions were conducted. Fasting venous blood samples
were obtained. Clinically important events such as
hypoglycaemia, drug-related adverse events, hospitalisa-
tion or deaths were recorded throughout the study
period. Details on the demographic and anthropometric
data collection procedures were already described in the
protocol paper [22].
Blood sampling and biochemistry profile
The baseline and outcome blood samples were analysed at
the Centre for Pathology and Diagnostic Research Labora-
tory (CPDRL), Universiti Teknologi MARA (UiTM) which
is an ISO 15189:2007 accredited laboratory (SAMM 688).
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Details of the blood sampling and laboratory analysis were
already described in the protocol paper [22].
Sample size calculation
The sample size was calculated using the randomised clus-
tered trial design with PASS software (Copyright (c) 2009
by Dr Jerry L. Hintze, All Rights Reserved). Based on the
results reported in previous studies [10, 12], the interven-
tion was expected to detect 25% change in the proportion
of subjects achieving target HbA1c < 6.5% from baseline
and between the intervention and control groups. As this
was a randomised cluster study, the ‘design effect’ was
taken into account during sample size calculation. The
intra-cluster correlation coefficients (ICC) in cluster pri-
mary care trials were generally lower than ρ = 0.05 [29]. If
m is the cluster size (assumed to be the same for all clus-
ters), then the inflation factor, or ‘design effect’ associated
with cluster randomisation is 1 + (m − 1)ρ [24]. Therefore,
for a cluster of 10, the ICC was translated into a design ef-
fect of 1.5. Considering this value, a sample size of 626 (313
in each arm) was obtained by sampling 10 clusters (5 inter-
vention vs. 5 control) with 63 subjects from each cluster to
detect 25% change in the proportion of subjects achieving
target HbA1c < 6.5% from baseline and between treatment
groups, with 91% power at 5% significance level. The test
statistic used was the two-sided Z-test (unpooled). After
allowing for 25% dropout rate, this study aimed to recruit a
total sample of 836 T2DM patients at baseline (i.e. 418 in
each arm and 84 from each clinic).
Statistical analyses
Intention to treat analysis was performed for both pri-
mary and secondary outcome measures. Missing vari-
ables were reviewed and determined if they were
missing at random. Multiple imputation was performed
using five imputed datasets for the missing variables at
follow-up: HbA1c (2.8% missing), systolic BP, diastolic
BP, BMI, TC, TG, LDL-c (6% missing) and HDL-c (4.2%
missing).
Continuous variables were summarised using means
and standard errors, while categorical variables were
summarised using counts and percentages. A generalised
estimating equation (GEE) method was used to account
for randomisation by practices (clustering) for all ana-
lyses. No other variable was added to adjust for cluster-
ing as stratification and matching of the practices was
done prior to randomisation to maximise the balance of
covariates between treatment groups. An independent
working model was used. Pooled treatment effects for
continuous variables were obtained using estimated mar-
ginal means.
Cut-off values for definition of outcome categories are
provided in the Additional file 2. Comparisons between
treatment groups for clinical outcome measures at
follow-up were adjusted for baseline values of the out-
come measures as well as the cluster effect [30]. The
baseline value of a clinical measurement is likely to be
the strongest predictor for its follow-up measurement
[31]. This adjustment was not determined a priori. Com-
parisons of outcome measures between treatment
groups for changes from baseline were adjusted for clus-
ter effect only. For all analyses, P values of less than 0.05
were considered statistically significant. Analyses were
performed using IBM SPSS Statistics for Windows, Ver-
sion 20.0 (IBM Corp., Armonk, NY, USA) and Stata
Statistical Software : Release 13.0 (College Station, TX:
Stata Corporation LP).
Results
Description of the site and population sample
Characteristics of the selected EMPOWER-PAR inter-
vention and control clinics are summarised in Table 2.
Distributions of clinics in terms of geographical loca-
tions, workload and staffing were similar in both arms.
A total of 888 T2DM patients were recruited at base-
line; 471 were in the intervention and 417 were in the
control group. At 1-year, 455 (96.6%) and 408 (97.8%)
patients in the intervention and control groups com-
pleted the study, respectively. In the intervention group,
16 (3.4%) patients were lost to follow; 10 patients moved
out from the area and 6 deaths were reported. The
causes of death were recorded as heart attack (3 pa-
tients), cardiac arrest due to heart failure (1 patient),
stroke (1 patient) and hyperosmolar hyperglycaemic
state (1 patient). In the control group, 9 (2.2%) patients
were lost to follow-up; 6 patients moved out and 3
deaths were reported. The causes of death were recorded
as heart attack (1 patient), stroke (1 patient) and dys-
pnoea (1 patient). There was no other clinically import-
ant event such as hypoglycaemia or drug-related adverse
event reported throughout the study period in both
groups. Figure 2 shows the The EMPOWER-PAR CON-
SORT Flow Diagram [24].
Table 3 shows the baseline sociodemographic and clin-
ical characteristics of the participants. The two groups
were comparable in terms of age, gender distribution,
ethnicity, education attainment, smoking status, coexist-
ing hypertension, history of cardiovascular events (myo-
cardial infarction, stroke and peripheral vascular
disease), duration of T2DM and duration of hyperten-
sion. However, the proportion of T2DM patients with
coexisting hyperlipidaemia was significantly lower in the
intervention compared to control group (intervention:
46.9% vs. control: 55.9%, P = 0.01). Patients in the inter-
vention group also had a significantly shorter duration
of hyperlipidaemia compared to the control group
(intervention: 1.8 years, SE ± 0.15 vs. control: 2.6 years,
SE ± 0.21, P = 0.001). The mean biochemical
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characteristics of the two groups were also comparable
at baseline, except for BMI and HDL-c. The proportions
of patients achieving biochemical targets were also com-
parable at baseline, except for TG.
Evaluation of the implementation fidelity
Table 4 summarises the pre-existing system of T2DM care
in the intervention clinics, changes made during the inter-
vention period and implementation fidelity as observed by
the facilitators. Two of the clinics had pre-existing dedi-
cated chronic disease clinic, while three clinics managed
their chronic cases together with acute cases in the general
outpatient clinic. Those clinics which already had a pre-
existing team strengthened their CDM Team through the
EMPOWER-PAR intervention, while the clinics without
any pre-existing team indentified new members to be
trained. Some of the clinics lost their team members during
the study period as they were transferred to other clinics
out of the region. However, new members were promptly
identified and retrained. The CDM delivery system was also
reviewed and strengthened in all of the intervention clinics.
With regards to T2DM CPG utilisation prior to the
intervention period, CPG was available in the FMS room in
most clinics. During the intervention period, the facilitators
observed that CPG QR was made available in each consult-
ation room and was utilised by team members for decision
making process during consultations. With regards to self-
management tool, patients carried the ‘mini green book’
prior to the intervention period. During the intervention
period, the clinics distributed the Global CV Risks Self-
Management Booklet (which was also known as the ‘red
book’) to all T2DM patients in their clinics. Utilisation of
the ‘red book’ by the CDM Team to support patients’ self-
management was also observed by the facilitators. In most
clinics, patients kept both the ‘red book’ and the ‘green
book’ during the study period. With regards to the imple-
mentation of the optional components, most of the clinics
continued with the pre-existing system of medical record
keeping. Two of the clinics were utilising the community
resources through their clinic advisory panel and continued
to do so during the intervention period. All intervention
clinics were also able to optimally adhere to the methods of
implementation which was proposed during the CDM
Workshops. Through the process of PAR, the FMS who led
the CDM Team in each clinic ensured that the intervention
was delivered as intended. A close working relationship was
also developed between the facilitators and the CDM Team
in each clinic.
Results by outcome
Table 5 shows the mean change in clinical outcomes at
1-year follow-up. The intervention group showed signifi-
cant reduction in the mean HbA1c compared to control,
which showed an increase in the mean HbA1c (interven-
tion: −0.1%, SE ± 0.06 vs. control: 0.2% SE ± 0.09, P =
0.003). For diastolic BP, although both groups showed an
increment at 1-year follow-up, the intervention group
had a significantly lower mean change in diastolic BP
compared to the control group (intervention: 0.4 mmHg,
SE ± 0.43 vs. control: 1.9 mmHg SE ± 0.47, P = 0.02).
Table 6 shows the distributions of patients according
to the outcome categories at 1-year follow-up. For
HbA1c, the proportion of patients in the ‘improving’ cat-
egory was higher in the intervention group (7.3%) com-
pared to the control group (3.2%), while the proportion
of patients in the ‘deteriorating’ category was lower in
the intervention group (4.2%) compared to the control
group (7.3%), and this trend was significant (P = 0.004).
There was no significant trend observed in the second-
ary outcome measures.
Table 7 shows the effectiveness of the EMPOWER-
PAR intervention and the changes in the proportion of
patients achieving primary and secondary outcome mea-
sures at 1-year follow-up. The change in the proportion
of patients achieving HbA1c target was significantly
higher in the intervention group compared to the
Table 2 Random selection of the eligible clinics and random
allocation of the selected clinics into intervention and control






















Urban 900 30 √ Intervention
Urban 900 28 Control
Pair
no. 2
Urban 600 27 √ Intervention
Urban 650 29 Control
Pair
no. 3




Urban 550 32 √ Intervention
Urban 500 33 Control
Pair
no. 5












Sub-urban 500 22 √ Intervention
Sub-urban 500 20 Control
Pair
no. 9




Sub-urban 350 21 √ Intervention
Sub-urban 400 19 Control
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control group (intervention: 3.0% vs. control: −4.1%, P <
0.002). There was no significant difference in the change
of the proportion of patients achieving target in all of
the secondary outcome measures between the interven-
tion and control groups. Patients who received the
EMPOWER-PAR intervention were twice more likely to
achieve HbA1c target compared to those in the control
group (adjusted OR 2.16, 95% CI 1.34–3.50, P < 0.002).
However, there was no significant difference found be-
tween the two groups in all of the secondary outcome
measures (BP, BMI, WC, TC, TG, LDL-c and HDL-c).
Results of the other outcome measures as stipulated in
the study protocol [22] will be reported in separate pa-
pers. These include the process of care for T2DM man-
agement, prescribing patterns, medication adherence
level, patients’ assessment of the chronic illness care,
qualitative analysis of health care providers’ perceptions,
attitudes, experiences and perceived barriers in imple-
menting the intervention and cost-effectiveness analysis
of the EMPOWER-PAR intervention.
Discussions
The CDM system change
The EMPOWER-PAR was one of the first pragmatic ran-
domised controlled trials of multifaceted interventions
based on the CCM conducted in a resource-constrained
public primary care setting in a developing country. This
study shows that the clinics receiving the EMPOWER-
PAR intervention package were capable of strengthening
their CDM system by implementing the obligatory inter-
vention components. These included strengthening the
roles of primary care providers in the CDM team, reinfor-
cing their adherence to T2DM CPG to support evidence
based decision making, and enhancing their skills to im-
prove patients’ self-management behaviours. These com-
ponents were designed based on the four CCM elements,
namely healthcare organisation, delivery system design,
decision support and self-management support. Interven-
tions involving delivery system design reported the largest
improvements in patient outcomes, followed by self-
management support, decision support and clinical infor-
mation system [10]. With regards to the optional compo-
nents, majority of the clinics continued with their pre-
existing system of chronic disease care.
The clinical outcomes
The EMPOWER-PAR intervention was proven to be ef-
fective in achieving the primary outcome by increasing
the proportion of patients who achieved their HbA1c
target. Patients in the intervention group were twice
Fig. 2 The EMPOWER-PAR CONSORT Flow Diagram
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more likely to achieve HbA1c target compared to those
in the control group (adjusted OR 2.16, 95% CI 1.34–
3.50, P < 0.002). These findings were similar to the VIDA
project, a randomised controlled trial using collaborative
learning based on the CCM in Mexico [32]. This study
showed that the proportion of patients achieving gly-
caemic control (HbA1c < 7%) increased from 28 to 39%
after 18-month intervention [32]. The interventions in
this study were directed at four components of the CCM
i.e. self-management support, decision support, delivery
system design and clinical information system [32]. An-
other randomised controlled trial of integrated manage-
ment of T2DM and depression showed that significantly
higher proportion of patients achieved HbA1c < 7% in
the intervention group compared to usual care (inter-
vention: 60.9% vs. usual care: 35.7%; P < 0.001) [33].
This study also showed that the greatest benefit of
intervention was to the poorly controlled patients as the
proportion in the ‘improving HbA1c’ category was
higher in the intervention (7.3%) compared to the con-
trol group (3.2%). This finding is clinically relevant to
the Malaysian primary care population as many patients
at younger age and those in the early stage of diabetes
are being treated in this setting. One of the main clinical
indicators for quality management set by the Malaysian
T2DM CPG, 5th edition 2015 [34] is to achieve ≥ 30%
proportion of T2DM patients in primary care with
HbA1c of ≤ 6.5%. Appraisal of evidence by the Malaysian
CPG Working Group found strong benefits for reduc-
tion of complications at or below this HbA1c level for
this group of patients in particular and for the Malaysian
population in general [34].
The intervention group showed a reduction in the
mean HbA1c while the control group showed an in-
crease instead, (intervention: −0.1% [SE = 0.06] vs. con-
trol: 0.2% [SE = 0.09], P = 0.003). Although the HbA1c
reduction was not clinically impressive, these findings
were similar to a randomised controlled trial of a multi-
faceted diabetes intervention based on the CCM con-
ducted in an underserved community in the United
States of America [35]. A modest decline in HbA1c was
Table 3 Baseline sociodemographic and clinical characteristics
of T2DM patients allocated to the intervention and control







Age, years; Mean (SE) 58 (0.48) 57 (0.5) 0.36
Gender; n (%)
Males 180 (38.2) 149 (35.7) 0.44
Females 291 (61.8) 268 (64.3)
Ethnicity; n (%)
Malays 242 (51.4) 190 (45.6) 0.26
Chinese 71 (15.1) 90 (21.6)
Indians 157 (33.3) 130 (31.2)
Others 1 (0.2) 7 (1.6)
Education attainment; n (%)
No education 50 (10.6) 45 (10.8) 0.84
Primary 187 (39.7) 157 (37.6)
Secondary 197 (41.8) 192 (46.1)
Tertiary 37 (7.9) 23 (5.5)
Smoking status; n (%)
Non-smoker 363 (77.1) 330 (79.1) 0.42
Current smoker 66 (14.0) 50 (12.0)
Ex-smoker 42 (8.9) 37 (8.9)
Comorbidity; n (%)
Hypertension 349 (74.1) 329 (78.9) 0.09
Hyperlipidaemia 221 (46.9) 233 (55.9) 0.01
History of myocardial infarction,
stroke or peripheral vascular disease
20 (4.2) 16 (3.8) 0.76
Duration of Medical Conditions, years; Mean (SE)
Duration of diabetes mellitus 6.5 (0.28) 6.8 (0.29) 0.41
Duration of hypertension 5.5 (0.32) 5.4 (0.32) 0.72
Duration of hyperlipidaemia 1.8 (0.15) 2.6 (0.21) 0.001
Biochemical characteristics at baseline; mean (SE)
HbA1c (%) 8.4 (0.09) 8.4 (0.09) 0.91
(mmol/mol)a 68.3 68.3
Systolic BP (mmHg) 139 (0.83) 138 (0.81) 0.60
Diastolic BP (mmHg) 80 (0.42) 80 (0.44) 0.49
BMI (kg/m2) 27.6 (0.23) 28.5
(0.29)
0.01
WC (cm) 95 (0.47) 96 (0.56) 0.19
TC (mmol/L) 5.3 (0.06) 5.3 (0.05) 0.65
TG (mmol/L) 2.2 (0.07) 2 (0.06) 0.09
LDL-c (mmol/L) 3.2 (0.05) 3.2 (0.05) 0.90
HDL-c (mmol/L) 1.1 (0.01) 1.2 (0.02) 0.01
Proportion achieving biochemical targets at baseline; %
HbA1c < 6.5%/< 48 mmol/mol 15.3 17.0 0.48
BP ≤130/80 mmHg 24.8 25.9 0.72
BMI < 23 kg/m2 15.7 12.7 0.20
Table 3 Baseline sociodemographic and clinical characteristics
of T2DM patients allocated to the intervention and control
groups, n = 888 (Continued)
WC <90 cm (Men) 11.3 12.5 0.58
<80 cm (Women)
TC≤ 4.5 mmol/L 26.8 26.9 0.97
TG≤ 1.7 mmol/L 45.4 52.8 0.03
LDL-c≤ 2.6 mmol/L 31.9 31.2 0.82
HDL-c≥ 1.1 mmol/L 60.9 66.7 0.08
aHbA1c in mmol/mol = [10.93 × HbA1c in %] – 23.5
Bold data represents statistically significant results i.e P value < 0.05
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Table 4 Implementation fidelity of the EMPOWER-PAR intervention
Intervention clinics Obligatory EMPOWER PAR intervention Optional EMPOWER PAR intervention
Creating/Strengthening a CDM team &
CDM delivery system
Utilising T2DM CPG Utilising the Global CV risks
self-management booklet
Utilising clinical information






Pre-existing dedicated chronic disease
clinic for T2DM & HPT (appointment
system, flow of patients, defaulter
tracing etc.)
1 medical officer, 2 nurses,
1 pharmacist and 2 attendants were
running this clinic.
CPG was available in the FMS
room.
Patients carried the ‘mini green
book’.
The clinic utilised the ‘green
book’ for medical record
keeping.
Participated in the National
Diabetes Registry program –a





Five existing members were trained in
the CDM Workshops, led by the FMS.
The CDM Team and the delivery
system were further strengthened.
CPG QR was made available in
hard and soft copies in each
consultation room and was
utilised by team members for
decision making.
The clinic fully utilised the
Global CV Risk Self
Management Booklet. The
book became popular
amongst patients and was









Clinic 2 Pre-existing system No pre-existing dedicated chronic
disease clinic.
Acute and chronic cases were seen in
the integrated general outpatient clinic.
A medical officer and a nurse were
in-charge of T2DM patients.
CPG was available in the FMS
room.
Patients carried the ‘mini
green book’.
The clinic utilised the ‘green
book’ for medical record
keeping.
Participated in the National
Diabetes Registry program – a
national audit for T2DM.












Five CDM Team members identified
and trained (medical officer, nurse,
medical assistant, dietician, and
pharmacist, led by the FMS).
Two members left at 6-month post
intervention, and two new members
retrained.
The clinic created a new CDM delivery
system (appointment system, flow of
patients, defaulter tracing etc.)
CPG QR was made available in
each consultation room and
was utilised by team members
for decision making during
consultation.
The clinic distributed and
utilised the Global CV Risk
Self Management Booklet
to support patients’ self-
management during
consultation.




Clinic 3 Pre-existing system No pre-existing dedicated chronic
disease clinic. Acute and chronic
cases were seen in the integrated
general outpatient clinic.
A medical officer and a nurse were
in-charge of T2DM patients.
CPG was available in each
consultation room; however,





Patients carried the ‘mini
green book’.
The clinic utilised the ‘green
book’ for medical record
keeping.
Participated in the National
Diabetes Registry program – a
national audit for T2DM.




















Table 4 Implementation fidelity of the EMPOWER-PAR intervention (Continued)
Changes made &
implementation fidelity
Five CDM Team members identified
and trained (medical officer, nurse,
medical assistant, dietician, and
pharmacist, led by the FMS).
The clinic created a new CDM delivery
system (appointment system, flow of
patients, defaulter tracing etc.)
CPG QR was made available in
hard and soft copies in each
consultation room and was
utilised by team members for
decision making.
Discussion on case
management according to the
CPG was done 2-monthly with
the FMS.
The clinic distributed and
utilised the Global CV Risk
Self Management Booklet




series were conducted, which
included diabetes conversation
maps and cooking demonstration.




Clinic 4 Pre-existing system Pre-existing dedicated chronic disease
clinic ran by a team of 7 health care
providers.
CPG was available in each
consultation room; with online
information on management
of T2DM.
Patients carried the ‘mini green
book’.
The clinic utilised the ‘green
book’ for medical record
keeping. Participated in the
National Diabetes Registry





Five existing members were trained in
the CDM Workshops, led by the FMS.
The CDM Team and the delivery
system were further strengthened
through team building and
cooperation.
CPG QR utilisation was further
strengthened in decision-making
process during consultation.
The clinic distributed and
utilised the Global CV Risk









Continued with the pre-
existing system.
Not developed.
Clinic 5 Pre-existing system No pre-existing dedicated chronic
disease clinic. Acute and chronic cases
were seen in the integrated general
outpatient clinic.
One staff nurse handled T2DM cases.
CPG was not available at the
nurses’ counter or in the doctors’
consultation rooms
Patients carried the ‘mini
green book’.
The clinic has its own diabetes
registry, prepared and
updated by the AMO
regularly. AMO was familiar
with SPSS and utilised it to
analyse patients’ data.
This is a new clinic










Five CDM Team members were
identified and trained. FMS was
transferred out; a staff nurse took over
the leadership of the team. Two
medical officers were assigned to see
patients with chronic diseases in the
morning every day.
CPG QR was made available in
the consultation rooms and the
nurses’ counter, and was utilised
by team members for decision
making.
The clinic distributed and
utilised the Global CV Risk




Some patients found it useful,
but some forgot to bring
along during follow-up
appointments.
The clinic utilised their registry















observed in the CCM group (−0.6%, P = 0.008) but not
in the provider-education-only group or usual care [35].
Another cluster randomised controlled trial to improve
T2DM care in community health centres in the United
States showed significant reduction in HbA1c (−0.45%,
95% CI −0.72 to −0.17) after 1–2 years of intervention
which incorporated CCM elements [36]. A systematic
review on the effectiveness of CCM-oriented diabetes in-
terventions found that CCM interventions were associ-
ated with a statistically significant greater mean
reduction in HbA1c (−0.46%, 95% CI 0.38 to 0.54; 46
studies) [10].
Table 5 Mean change in clinical outcomes of T2DM patients at 1-year follow-up














HbA1c (%) 8.4 (0.09) 8.3 (0.09) −0.1 (0.06) 8.4 (0.09) 8.5 (0.1) 0.2 (0.07) 0.003
(mmol/mol)d 68.3 67.2 −22.4 68.3 69.4 −21.3
Systolic BP (mmHg) 139 (0.83) 139 (0.86) −0.3 (0.78) 138 (0.81) 140 (0.92) 1.7 (0.75) 0.08
Diastolic BP (mmHg) 80 (0.42) 81 (0.44) 0.4 (0.43) 80 (0.44) 82 (0.5) 1.9 (0.47) 0.02
BMI (kg/m2) 27.6 (0.23) 27.8 (0.23) 0.2 (0.08) 28.5 (0.29) 28.6 (0.27) 0.1 (0.14) 0.64
WC (cm) 95 (0.47) 97 (0.56) 2 (0.33) 96 (0.56) 97 (0.64) 1.2 (0.37) 0.08
TC (mmol/L) 5.3 (0.06) 5.2 (0.05) −0.1 (0.05) 5.3 (0.05) 5.2 (0.05) −0.1 (0.05) 0.90
TG (mmol/L) 2.2 (0.07) 2.1 (0.05) −0.1 (0.06) 2 (0.06) 2 (0.05) −0.1 (0.05) 0.64
LDL-c≤ 2.6 mmol/L 3.2 (0.05) 3.1 (0.05) −0.02 (0.04) 3.2 (0.05) 3.1 (0.04) −0.03 (0.04) 0.84
HDL-c≥ 1.1 mmol/L 1.1 (0.01) 1.2 (0.01) 0.02 (0.01) 1.2 (0.02) 1.3 (0.02) 0.05 (0.02) 0.09
Intention to treat analysis was performed to determine the mean change in clinical outcome measures
aChange from baseline (standard error) unadjusted
bMean change from baseline compared between treatment groups, adjusted for cluster effect using GEE
cSignificance of intervention term in model
dHbA1c in mmol/mol = [10.93 × HbA1c in %] – 23.5
Bold data represents statistically significant results i.e P value < 0.05
Table 6 Distribution of T2DM patients according to the outcome categories at 1-year follow-up
Outcome
Categories
Group Deteriorating Poor, no change Good, no change Improving P value
n (%) n (%) n (%) n (%)
Primary outcome
HbA1c Intervention 20 (4.2) 365 (77.4) 52 (11) 34 (7.3) 0.004
Control 31 (7.3) 333 (79.8) 40 (9.7) 13 (3.2)
Secondary outcome
BP Intervention 58 (12.2) 298 (63.4) 59 (12.6) 56 (11.8) 0.15
Control 61 (14.6) 268 (64.4) 47 (11.3) 41 (9.7)
BMI Intervention 18 (3.9) 380 (80.8) 56 (11.8) 17 (3.5) 0.37
Control 10 (2.5) 357 (85.6) 43 (10.2) 7 (1.7)
WC Intervention 16 (4.8) 286 (86.4) 17 (5.1) 12 (3.6) 0.72
Control 15 (4.5) 285 (85.8) 24 (7.2) 8 (2.4)
TC Intervention 48 (10.1) 284 (60.2) 78 (16.6) 61 (13) 0.93
Control 40 (9.6) 255 (61.2) 72 (17.2) 50 (12)
TG Intervention 65 (13.8) 185 (39.3) 149 (31.6) 72 (15.2) 0.32
Control 52 (12.5) 144 (34.6) 168 (40.2) 53 (12.6)
LDL-c Intervention 56 (12.4) 249 (54.8) 89 (19.5) 61 (13.3) 0.45
Control 50 (12.7) 228 (57.3) 74 (18.5) 46 (11.5)
HDL-c Intervention 44 (9.4) 134 (28.4) 243 (51.5) 50 (10.7) 0.11
Control 34 (8.1) 96 (23) 244 (58.6) 43 (10.4)
Intention to treat analysis was performed for primary and secondary outcome measures
Bold data represents statistically significant results i.e P value < 0.05
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This study however, did not show significant improve-
ment in the secondary outcome measures i.e. the propor-
tion of patients achieving targets BP, BMI, WC, TC, TG,
LDL-c and HDL-c. This is contrary to the findings of a
systematic review which found that CCM interventions
were associated with significant greater reductions in sys-
tolic BP (−2.2 mmHg, 95% CI 0.9 to 3.5; 26 studies), dia-
stolic BP (−1.3 mmHg, 95% CI 0.6 to 2.1; 25 studies) and
TC (−0.24 mmol/L, 95% CI 0.06 to 0.41; 17 studies) [10].
The EMPOWER-PAR intervention was proven to be ef-
fective in improving the primary outcome i.e. the gly-
caemic control, but not the secondary outcome measures.
However, only the primary outcome was considered in the
sample size calculation for this study. Therefore, this study
may not be powered to detect the differences in the sec-
ondary outcome measures. Another explanation for these
findings could be due to the traditional focus of diabetes
care in Malaysia towards glycaemic control, while the
management of coexisting CV risk factors has been shown
to be suboptimal [8]. In EMPOWER-PAR, although util-
isation of the Global CV Risk Self-Management Booklet
was part of the intervention, its effectiveness in improving
the secondary outcome measures has not been demon-
strated. When resources were limited, the CDM Team in
the intervention clinics may be more focused to improve
the HbA1c target, but not the other clinical outcomes.
This highlights the need to channel the resources appro-
priately and to continuously train primary care providers
to change the paradigm of diabetes care towards the glo-
bal CV risk factors approach [37].
Strengths and limitations of the study
The key strength of EMPOWER-PAR was its pragmatic
cluster randomised trial design, which was expected to
measure the degree of beneficial effect of the interven-
tion in real life clinical practice. In pragmatic trials, a
balance between external validity (generalisability of the
results) and internal validity (reliability or accuracy of
the results) needs to be achieved [21]. Frequently, cluster
randomised trials have a risk of bias due to the alloca-
tion of intervention by clusters [38], thus limiting their
internal validity. The EMPOWER-PAR reduced the like-
lihood of bias in allocation by matching the clinics for
their geographical locations, staffing and workload.
Matching in pairs based on the similarity of the covari-
ates prior to random treatment assignment can greatly
improve the efficiency of causal effect estimation [39].
Therefore, when pairing is feasible, clusters should be
paired prior to randomisation to minimise bias and to
improve efficiency, power and robustness [40]. In this
study, the clinics were matched prior to sampling, hence
resulting in the comparability of clinics recruited into
the study. As randomisation was subsequently done
based on pairs of clinics with matched characteristics,
this further reduced the risk of bias in cluster allocation.
In addition to limiting the risk of bias at the design
stage, the analysis of the results took into account the ef-
fect of clustering. Baseline covariates between the inter-
vention and control groups were well balanced for
almost all covariates suggesting a lack of selection bias
during recruitment. The low rates of loss to follow-up
Table 7 Effectiveness of the EMPOWER-PAR intervention in achieving the primary and secondary outcome measures at 1-year
follow-up
Clinical outcome measures Intervention Control Model summaryb
Baseline % Follow-up % Changea % Baseline % Follow-up % Changea % Odds Ratio (95% CI)c P valued
Primary outcome
HbA1c <6.5%/ 15.3 18.3 3.0 17.0 12.9 −4.1 2.16 (1.34, 3.50) 0.002
<48 mmol/mol
Secondary outcomes
BP≤ 130/80 mmHg 24.8 24.4 −0.4 25.9 21.1 −4.8 1.27 (0.91, 1.78) 0.16
BMI < 22.9 kg/m2 15.7 15.4 −0.3 12.7 11.9 −0.8 1.27 (0.70, 2.31) 0.44
WC <90 cm (M) 11.3 8.8 −2.5 12.5 9.6 −2.9 1.01 (0.53, 1.93) 0.97
<80 cm (F)
TC≤ 4.5 mmol/L 26.8 29.6 2.8 26.9 29.2 2.3 1.03 (0.74, 1.43) 0.86
TG≤ 1.7 mmol/L 45.4 46.9 1.5 52.8 52.8 0 0.87 (0.65, 1.18) 0.38
LDL-c≤ 2.6 mmol/L 31.9 32.5 0.6 31.2 29.8 −1.4 1.15 (0.83, 1.60) 0.41
HDL-c≥ 1.1 mmol/L 60.9 62.2 1.3 66.7 69.0 2.3 0.79 (0.56, 1.12) 0.19
Intention to treat analysis was performed for primary and secondary outcome measures
aChange in the proportion of patients achieving clinical outcomes: Follow-up - Baseline
bEstimates were derived using GEE. Results were adjusted for baseline values and cluster effect
cOdds for achieving clinical outcome measures in the intervention group compared with control group
dSignificance of intervention term in model
Bold data represents statistically significant results i.e P value < 0.05
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(2–3%) minimised selection bias as well. Given its prag-
matic trial design and lack of bias, the results of this
study may therefore be generalisable to other Malaysian
public primary clinics in resource-constrained setting
which share similar characteristics.
The EMPOWER-PAR utilised resources which were
readily available within the public primary care system
in its intervention components. Despite the modest re-
sults obtained, this study shows that even without sub-
stantial additional resources, developing countries can
still effect a change in clinical practice. Findings of this
study provide critical supportive information for any de-
veloping country with limited resources, as the interven-
tion would probably be inexpensive to replicate.
However, cost-effectiveness analyses are required to in-
form further decision making on the value of the
EMPOWER-PAR intervention, and this will be reported
in a separate paper.
Another key strength of this study is the PAR ap-
proach. In PAR, the researchers attempt to democratise
the research process [20]. The iteration of reflection and
self-analysis of the intervention, together with the power
sharing in the research process are the main characteris-
tics of PAR [20]. In this study, primary care providers in
the intervention clinics who were passive players in the
beginning became active players as the study progressed.
The PAR approach required active participation of the
CDM Team from each clinic to design, propose and im-
plement the intervention. The FMS who led the CDM
Team in each clinic was also involved in the designing
process and ensured that the intervention was delivered
as intended. The process of PAR allowed the primary
care providers in this study to have increased autonomy
to design the intervention plan based on the CCM ele-
ments and made the choice of actions within their con-
straints to improve their patients’ health outcomes.
Successful implementation of a complex, multifaceted
CCM intervention may depend not only on the
provision of appropriate resources and the development
of effective systems and processes, but also on the vari-
ous stakeholders who will interpret and influence the
implementation process [41]. Human factors, including
the role of healthcare providers and their leaders who
can either facilitate or impede successful implementa-
tion, should be considered [41]. The PAR approach also
allowed collegial environment to develop between facili-
tators and the CDM Team in this study. This factor may
have promoted better reflective practice and could have
contributed towards the improved outcomes. In addition
to ensuring appropriate resources, successful implemen-
tation of CCM interventions would highly depend on
whether the intervention is acceptable to both patients
and healthcare providers [41]. Primary care providers
must be actively involved in the change process to
ensure that patients are supported throughout the im-
plementation of CCM interventions.
Limitations of this study include the challenge to en-
sure implementation fidelity of the EMPOWER-PAR
intervention. Monitoring the intervention and ensuring
its implementation posed a great challenge to the re-
searchers in this study. It required multiple visits and
encounters with primary care providers in the interven-
tion clinics to ensure that the intervention was delivered
as intended. Some of the intervention clinics faced con-
straints such as high staff turnover, high workload and
limited consultation time. Despite the constraints, all
five clinics were able to optimally adhere to the pro-
posed intervention plan and delivered the obligatory
components as intended. Evidence have shown that
moderate adherence to a prescribed protocol was more
predictive of good intervention outcomes than a perfect
level of adherence [42]. This suggests that some level of
practitioner flexibility and adaptability is needed to meet
local and individual needs when implementing interven-
tions in different populations within different contexts
[28]. The optimal implementation fidelity of the
EMPOWER-PAR intervention was achieved through tai-
loring the needs and constraints of each individual clinic.
Variations in implementation between each clinic were
also found to be minimal and therefore, it is unlikely
that this would have influenced the final outcomes.
Implications for clinical practice, future research and
policy change
The EMPOWER-PAR has demonstrated that multifa-
ceted interventions based on the CCM was effective in
improving the proportion of T2DM patients achieving
HbA1c target in a resource-constrained public primary
care setting. Due to its pragmatic design which utilised
readily available resources, the results may be generalis-
able to other primary care clinics in resource-
constrained setting which share the same characteristics.
However, this study falls short in demonstrating effect-
iveness in improving the secondary outcomes. This high-
lights the pressing need to change the paradigm of
diabetes care among primary care providers towards the
global CV risk factors approach, as there were conclu-
sive evidence that BP, lipid and weight lowering reduced
cardiovascular morbidity and mortality among T2DM
patients [37].
The primary outcome of this study was set according
to the recommendation by the Malaysian T2DM CPG,
4th edition 2009 [27] to avoid confusion among the
healthcare providers. The HbA1c target of < 6.5% is quite
tight and it is difficult to achieve in real life clinical prac-
tice without predisposing patients to hypoglycaemia.
This strict target may also be challenged by recent evi-
dence and other international guidelines which
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recommend target HbA1c of < 7.0% (<53 mmol/mol)
[43, 44]. However, the recent Malaysian T2DM CPG,
5th edition 2015 still recommends HbA1c target of ≤
6.5%, especially for patients with shorter duration of dia-
betes, no evidence of significant CVD, longer life expect-
ancy and minimal risk of hypoglycaemia [34]. Majority
of patients being treated in primary care fit these pro-
files. In clinical practice, however, HbA1c target should
be individualised according to the complexities of indi-
vidual patient needs to minimise the risk of
hypoglycaemia [34].
This study invites further research question whether the
intervention and its beneficial effect would be sustainable
in the long term. Given the constraints in the Malaysian
public primary clinics such as high staff turnover, further
research which includes a longer duration of intervention
is needed to evaluate the sustainability of the intervention
and its effectiveness. Further research which includes pub-
lic primary care clinics in other parts of Malaysia, which
may have different resource constraints, is also needed to
provide more robust evidence on the effectiveness of the
EMPOWER-PAR intervention.
Policy change and better resource allocations are
needed to implement these multifaceted interventions in
the Malaysian public primary care setting to ensure its
sustainability. There is a need for a holistic understand-
ing among policy makers, healthcare providers and pa-
tients, of the complexity of diabetes care in order to
instigate change in the management of diabetes in the
community [45]. Decision makers need to be able to ap-
praise research evidence judiciously to select cost-
effective interventions which could potentially improve
outcomes of diabetes care in the community [45]. It is
hoped that the evidence from this study will provide a
platform to instigate the much needed policy change
and resource allocations to support diabetes care in the
Malaysian public primary care setting.
Conclusions
Findings from this pragmatic clinical trial provide ob-
jective evidence of the effectiveness of the EMPOWER-
PAR intervention in improving the proportion of T2DM
patients achieving glycaemic target in real life public pri-
mary practice in Selangor and Kuala Lumpur, Malaysia.
The results may be generalisable to other Malaysian
public primary clinics or other clinics in resource-
constrained setting which share the same characteristics.
As the intervention utilised readily available resources, it
would probably be inexpensive to replicate. However,
given the constraints in the Malaysian public primary
clinics such as high staff turnover, further research is
needed to evaluate whether the intervention and its
beneficial effect would be sustainable in the long term.
Finally, we hope that the evidence from this study will
influence policy change and resource allocations to sup-
port management of T2DM in the Malaysian public pri-
mary care setting.
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